REGENXBIO Closes $370M+ Gene Therapy Eye Care Collaboration Agreement with AbbVie for Wet AMD and Diabetic Retinopathy

Published on :

REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its Collaboration and License Agreement with AbbVie to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.

Johns Hopkins Technology Ventures Boosts Maryland Life Sciences

Published on :

Johns Hopkins Technology Ventures (JHTV) has had a significant impact on the Maryland life sciences ecosystem since its founding in 2014, assisting with hundreds of licensed therapeutics in development and backing nearly 200 startups that have collectively nearly $3 billion in venture capital funding, 30% of which has remained in the state.